Operator: Our next question comes from Zhi Shu from Berenberg. Your line is now open.
Zhi Shu: Good morning. Thanks for taking my question. I want to ask a question related to market access. Do you anticipate a separate code for ISN and when the product is going to launch? And then related to that, what’s your expectation for gross to net? Thanks very much.
Kate Haviland: Thank you for that question. And I’ll hand over the question on the codes to Philina and then Mike can take gross to that.
Philina Lee: Yeah, I mean I think at the heart of your question is what kind of access we anticipate as IFM comes to market. And just to answer that head on, we expect and are highly focused on maintaining strong patient access to ISM. Today, we have virtually unencumbered payer coverage. And we expect based on the payer market research that we’ve done that, that’s not expected to change or limit the target patients that should adopt. And your specific question about the code, no, at this point, we don’t expect a new code for SM.
Kate Haviland: So just to be really clear, there’s just one code for SM and you can’t distinguish between subtypes within it. And so that’s what we’d expect to continue. Mike, do you want to take the gross to net?
Mike Landsittel: Yeah, for gross to net, so currently with AYVAKIT, we see a gross to net range in about the mid-80% range as per gross margin. In the near term, we expect that to continue once we announce pricing for ISM and get further into that launch. We said there will be some flexibility and how we think about contracting going forward. If we need to do that, that could lead to some erosion, but the mid-80s is a good starting point.
Kate Haviland: And I think on the ISM market, it’s also important to remember, there’s going to be puts and takes here, right? So the ISM market, we have a larger percentage of our patients are covered by commercial insurance. So there – that will give us some tailwinds. And then we have that room, as Mike mentioned, that if we need to do any type of contracting to ensure that seamless market access, which we may or may not, but we have some space there as well. So it is – there is a slightly different payer mix in this group than we’ve seen in advanced SM.
Zhi Shu: Thank you very much.
Operator: Our next question today comes from Ami Fadia from Needham. Your line is now open.
Ami Fadia: Hi, good morning. Thanks for taking the question. Just ahead of the Quad AI data presentation, I wanted to just sort of understand how to interpret some of the data that will be presented there. I mean it’s clear that there’s a huge heterogeneity in the patient population base with each patient having a very different symptom domains bothersome. So how do we take the change in TSS score across each of the domains that you will be presenting at the meeting and think about how clinically meaningful it may be for an individual patient? And how will physicians really interpret that data? Thank you.
Kate Haviland: Christy, do you want to take that?
